Click here to view online. Add this email to your safelist.
AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
27 July 2021
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
